Perhaps at some point we see a expansion of the Tacti Mel trial...

Perhaps at some point we see a expansion of the Tacti Mel trial ,to a ph2 ,data looked very promising.
Tacti Mel
Commenting on the positive results, Dr. Triebel said, “The combination therapy with efti shows very encouraging efficacy signals of synergy with KEYTRUDA along with a favourable safety profile so far in this high-risk patient population. Patients are responding well to the combination treatment, their tumours are shrinking and not growing back over a long follow up period. In addition, we have seen the complete disappearance of all target tumour lesions for six patients plus one patient with a metabolic complete response on the PET-scan. The efficacy data is now final with a long follow up, the safety assessment is ongoing.i

Immp